RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
Regulatory Agency Hub

India CDSCO Updates

The latest guidances, approvals, and safety alerts from India CDSCO, curated by automated regulatory intelligence.

REGULATION
28.10.2026 G.S.R. 954(E)_Draft​ Amendment of Rule 43A of the Drugs Rules, 1945 to include various ICDs/Port/SEZs for the import of Drugs/ Medical Devices/ Cosmetics in India
CDSCO (India) • Published: Oct 28, 2026

Amends Rule 43A of the Drugs Rules, 1945 to expand the list of approved inland container depots (ICDs), ports, and SEZs that may be used for the import of…

manufacturing
quality
+3
View update →
REGULATION
28.10.2026 G.S.R. 955(E)_Draft Notification for amendment in the Drugs Rules, 1945 for requirement of an authorised person responsible for batch release of product
CDSCO (India) • Published: Oct 28, 2026

Establishes a proposal to amend the Drugs Rules, 1945 to require an authorized person responsible for batch release of drug products.

manufacturing
quality
View update →
REGULATION
2026.10.28 G.S.R. 951(E)_Notification regarding rationalization of shelf life under Rule 31 of Drugs Rules, 1945
CDSCO (India) • Published: Oct 28, 2026

Rationalizes how shelf life is set under Rule 31 of the Drugs Rules, 1945, potentially requiring applicants to align stability evidence and shelf-life…

quality
View update →
NOTICE
Appointment of Central Compounding Authority Order
CDSCO (India) • Published: Oct 28, 2026

Appointment of a Central Compounding Authority suggests India may establish or formalize centralized oversight for compounding activities, potentially…

manufacturing
quality
+3
View update →
NOTICE
Misleading or false claims of the product FatX solution registered under COS-2 vide RC no. RC/COS-003300 by the firm M/s Tekno Midas Aesthetics
CDSCO (India) • Published: Oct 28, 2026

Highlights enforcement attention on the FatX solution’s registration under COS-2 (RC/COS-003300) due to misleading or false product claims, which may trigger…

safety
labeling
+2
View update →
NOTICE
Digital Monitoring System on the ONDLS portal for monitoring the supply chain of high-risk solvents.
CDSCO (India) • Published: Oct 27, 2026

Implements a digital monitoring approach via the ONDLS portal to track the supply chain of high-risk solvents, strengthening oversight and traceability of…

manufacturing
quality
+1
View update →
NOTICE
Strict compliance with the Drugs Rules, 1945, for testing of raw materials and finished formulations
CDSCO (India) • Published: Oct 27, 2026

Reinforces the expectation that India-regulated drug manufacturers strictly comply with the Drugs Rules, 1945 when conducting testing for both raw materials…

manufacturing
quality
+2
View update →
NOTICE
Misleading or false claims of the product FatX solution registered under COS-2 vide RC no. RC/COS-003300 by the firm M/s Tekno Midas Aesthetics
CDSCO (India) • Published: Oct 26, 2026

Raises regulatory concern regarding misleading or false claims associated with FatX solution, registered under COS-2 (RC No.

labeling
safety
View update →
NOTICE
WHO Alert on falsified DEFITELIO (Defibrotide) 80 mg/ml concentrate for solution for infusion, B. No. 24GC01A, Exp date 04/2027, Mfg by: Patheon, II Trav. sx Via Morolense, 5, 03013 Ferentino (FR) Italy and Marketing authorisation holder: Gentium S.r.l, Piazza XX Settembre, 2, 22079 Villa Guardia (Como) Italy and identified in India
CDSCO (India) • Published: Oct 26, 2026

Notifies that WHO has issued an alert regarding falsified DEFITELIO (defibrotide) 80 mg/mL concentrate for solution for infusion, identified in India.

rare_diseases
hematology
+4
View update →
NOTICE
List of Ethics Committees cancelled by CLA
CDSCO (India) • Published: Oct 19, 2026

Cancels a specified list of Ethics Committees (ECs) recognized by the CLA, which may affect the acceptability of ethics review for clinical trial approvals and…

View update →
NOTICE
Clarification regarding requirement of Export NOC for already approved r-DNA products.
CDSCO (India) • Published: Oct 14, 2026

Clarifies that an Export NOC requirement (as interpreted/applied by CDSCO) for r-DNA products may not apply uniformly to products that are already approved…

manufacturing
quality
+1
View update →
REGULATION
2026.10.13 S.O. 5617(E), Notification of Government Analysts for veterinary vaccines at CCSNIAH, Baghpat
CDSCO (India) • Published: Oct 13, 2026

Notifies the appointment of Government Analysts for veterinary vaccines at CCSNIAH, Baghpat, thereby formalizing the laboratory/analytical authority…

infectious_disease
immunology
+4
View update →
REGULATION
S.O. 5617(E), Notification of Government Analysts for veterinary vaccines at CCSNIAH, Baghpat
CDSCO (India) • Published: Oct 13, 2026

Notifies the appointment of Government Analysts for veterinary vaccines at CCSNIAH, Baghpat, thereby clarifying the authorized laboratory/official testing…

View update →
NOTICE
Draft Guidance document for Manufacturers of In-vitro diagnostic Medical device for stakeholders comment
CDSCO (India) • Published: Oct 9, 2026

Draft guidance for stakeholders on India CDSCO regulatory expectations for manufacturers of in-vitro diagnostic (IVD) medical devices, intended to solicit…

manufacturing
quality
+3
View update →
NOTICE
Surrender of Cosmetic Registration Certificate No. RC/COS-005067 dated 05.07.2024
CDSCO (India) • Published: Oct 6, 2026

Cosmetic Registration Certificate No. RC/COS-005067 dated 05.07.2024 has been surrendered, indicating the certificate holder is discontinuing regulatory…

dermatology
View update →
REGULATION
2026.09.28 G.S.R. 861(E)_Draft proposal for Change in conditions of Retail and Wholesale license w.r.t. advertisement.
CDSCO (India) • Published: Sep 28, 2026

Drafts changes to the conditions attached to India CDSCO retail and wholesale licensing specifically in relation to advertisements.

safety
labeling
View update →
NOTICE
Indiscriminate use of painkillers (NSAIDs), antibiotics and associated risk of Chronic Kidney Disease
CDSCO (India) • Published: Sep 22, 2026

Indiscriminate use of NSAIDs and antibiotics is being highlighted as a safety concern linked to increased risk of Chronic Kidney Disease (CKD), implying the…

safety
labeling
+2
View update →
SAFETY ALERT
LIST OF REGISTRED BA-BE STUDY CENTRE & BIO-ANALYTICAL LABORATORY under NDCT Rules 2019
CDSCO (India) • Published: Sep 18, 2026

Maintains/announces an official list of registered BA-BE study centres and bio-analytical laboratories for conducting bioavailability/bioequivalence work under…

clinical
manufacturing
+3
View update →
NOTICE
Public Health alert against the use of unauthorised Cosmetics Products
CDSCO (India) • Published: Sep 14, 2026

Alerts regulated entities and the public to avoid use of cosmetics products that are not authorized by CDSCO, signaling enhanced compliance and potential…

View update →
REGULATION
2026.09.08 G.S.R. 791(E)_Draft notification for amendment in the Drugs Rules 1945 regarding mandatory installation of CCTV surveillance system at sales premises
CDSCO (India) • Published: Sep 8, 2026

Mandates amendments to India’s Drugs Rules, 1945 to require the mandatory installation of CCTV surveillance systems at drug sales premises.

View update →

Get India CDSCO alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service
  • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.